Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Our investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. We make direct equity investments across all stages of development and types of financing rounds.

Aptinyx

Dice Therapeutics

Entrada Therapeutics

Orchard Therapeutics

Pliant Therapeutics

Precision BioSciences

Pyxis Oncology

Agent Capital

We are excited for Eli Lilly and Company to acquire our portfolio company, DICE Therapeutics. Congratulations to the entire DICE Therapeutics team and  Kevin Judice for their dedication! Agent Capital is honored to have been part of this exciting journey, and we look forward to DICE Therapeutics’ next chapter as a part of Eli Lilly and Company to accelerate the development of novel oral therapeutics to treat autoimmune diseases.

Read more: https://bit.ly/3CCfhzE

Congratulations to the Pyxis Oncology team on this milestone!

Congratulations to Cyrus Biotechnology's scientist, Erik Procko, and the company's lead ACE2-Fc Fusion protein COVID-19 therapeutic for being featured in Science news article!
https://lnkd.in/gGkF8iWD

Person Schema

U.S. Server Location

Gravatar Profiles

Founder and Managing Partner

Geeta Vemuri

General Partner, Co-Founder

Preston Noon

Head of Investor Relations

Julie Gionfriddo

Executive Assistant Office Manager

Heather Hamilton

Partner

Jacopo Leonardi

Co-Founder & Managing Partner

Co-Founder & General Partner

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

Pyxis Oncology is  a developer of antibody therapeutics intended to promote the body's immune response to cancer.

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

Precision BioSciences is a biotechnology company dedicated to improving life.

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Female Founded Late Stage Venture Investors with Investments in Europe

Venture Stage Investors with Investments in West Coast

Female Founded Early Stage Venture Investors with Investments in Research Triangle

Massachusetts Late Stage Venture Investors

Agent Capital Fund I

Cambridge

Massachusetts

United States

North America

Metsera gets $215m for obesity trials, and other financings

TRexBio Announces $84 Million Series B

Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates

Cantai Therapeutics: Seed Funding Completed In Round Co-Led By Agent Capital And 82VS

Spain

Europe

United Kingdom

Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Our investment areas of focus are new products and technologies for oncology, immunology, neurology, and rare disease indications. We make direct equity investments across all stages of development and types of financing rounds.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	dd36b084
crunchbase profile	general	Nov 25, 2024 11:36 AM	f6bc656c
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	559a350b
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AGENTCAPITAL

Agent Capital